XCNQ
BLAB
, Last price
CAD
Name
Britannia Life Sciences Inc
Chart & performance
P/E
—
P/S
—
EPS
0.07
Vol. 1Y
—
Shs. 5Y
15.89%
Rev. 5Y
-19.73%
Div Yld LY
—
Div Yld TTM
—
Revenues
475k
+28.58%
Net income
13m
+76.85%
CFO
-1m
L-55.86%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Britannia Life Sciences Inc., headquartered in Toronto, Canada, offers specialized services in rigorous product evaluation, comprehensive safety analysis, and adherence to regulatory standards. The company supports businesses within the cosmetics, nutraceutical, and consumer packaged goods (CPG) sectors, operating extensively throughout the United Kingdom and various international markets.
Key people
Ryan Rocca
Chief Executive Officer · since 2019
Chief Financial Officer · since 2016
Daniel Cloutier
Director · since 2017
Director · since 2016
Director · since 2019
Scott Lawrence Secord
Executive Chairman of the Board · since 2018
Legal address
120 Adelaide Street West
Suite 2400
Toronto, ON M5H 1T1
CA
Suite 2400
Toronto, ON M5H 1T1
CA
Headquarters
120 ADELAIDE ST WEST
SUITE 2400
TORONTO, ON M5H 1T1
CA
SUITE 2400
TORONTO, ON M5H 1T1
CA
Previous name
LUMINOR MEDICAL TECHNOLOGIES INC.
Previous name
MIRACULINS INC.
Previous name
Rise Life Science Corp.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||